|
KR20140059859A
|
|
Methods for monitoring responsiveness to anti-smad7 therapy
|
|
CA2752623A1
|
|
Alkylamido compounds and uses thereof
|
|
CN102216458A
|
|
Antisense compositions and methods of making and using same
|
|
WO2009132821A1
|
|
Interleukin (il-21) binding proteins and methods of making and using same
|
|
BRPI0821331A2
|
|
Compounds for selective treatment of intestinal immunoinflammatory component of celiac disease
|
|
EP2130547A1
|
|
IL-25 for use in the treatment of inflammatory diseases
|
|
EP2106801A1
|
|
IL-25 for use in the treatment of inflammatory diseases
|
|
IE20070928A1
|
|
Multi target ligands
|
|
IE20070129A1
|
|
Ppar-gamma agonists stimulate enteric defensin expression
|
|
NZ592228A
|
|
Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
|
|
CN101243043A
|
|
Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
|
|
UA102210C2
|
|
(±)-2-HYDROXY-3-(3'-AMINOPHENYL) PROPIONIC ACID AS A COMPOUND SPECIFIC FOR PPARγ RECEPTORS AND THE EGF RECEPTORS AND USE THEREOF IN MEDICAL FIELD
|
|
IE20060448A1
|
|
Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
|
|
BRPI0516661A
|
|
interleukin-21 antigenic epitopes, related antibodies and their use in the medical field
|
|
CA2520541A1
|
|
Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
|
